




Norepinephrine U.S. Market



Norepinephrine Monthly U.S. Vials Month Ended:			
Drug	June (6/30/2019)	July (7/31/2019)	August (8/31/2019)
Norepinephrine (Claris)	403,751	442,244	439,843
Norepinephrine (Mylan)	90,720	91,310	96,490
Norepinephrine (Teva)	87,910	93,840	86,440
Levophed (Pfizer)	50,320	60,110	64,080
Norepinephrine (Hikma)	13,370	33,090	41,510
Norepinephrine (Sandoz)	8,560	6,830	13,140
Norepinephrine (Amneal)		270	1,090
Total	654,631	727,694	742,593

Drug	Annualized Vials (Based on Trailing 1 Month)	% of Vials
Norepinephrine (Claris)	5,278,116	59%
Norepinephrine (Mylan)	1,157,880	13%
Norepinephrine (Teva)	1,037,280	12%
Levophed (Pfizer)	768,960	9%
Norepinephrine (Hikma)	498,120	6%
Norepinephrine (Sandoz)	157,680	2%
Norepinephrine (Amneal)	13,080	0%
Total	8,911,116	100%



Drug	Annualized WAC Sales (Based on Trailing 1 Month)	% of WAC Sales
Norepinephrine (Claris)	\$ 46,183,515	41%
Norepinephrine (Mylan)	\$ 20,215,427	18%
Norepinephrine (Teva)	\$ 18,691,786	16%
Levophed (Pfizer)	\$ 15,556,061	14%
Norepinephrine (Hikma)	\$ 9,969,374	9%
Norepinephrine (Sandoz)	\$ 2,870,880	3%
Norepinephrine (Amneal)	\$ 235,702	0%
Total	\$ 113,722,745	100%